Peritoneal Glucose Uptake Reduction by Sodium-Glucose Co-Transporter 2 Inhibitors in Clinical Peritoneal Dialysis.

INTRODUCTION

In peritoneal dialysis (PD), managing peritoneal glucose uptake is a clinical challenge, as the uptake leads to peritoneal ultrafiltration loss. Peritoneal expression of sodium-glucose co-transporter 2 (SGLT2) suggests that SGLT2 inhibitors, a class of antidiabetic agents, may offer a solution.

METHODS

In 12 PD patients, we examined the influence of dapagliflozin, an SGLT2 inhibitor, on peritoneal equilibration test.

RESULTS

The volume of drainage and the total glucose content in drainage were larger in the test with dapagliflozin than in that without dapagliflozin (2.41 ± 0.16 vs. 2.23 ± 0.20 L, p = 0.011 and 16.9 ± 3.8 vs. 14.5 ± 3.7 g, p = 0.005, respectively).

CONCLUSION

SGLT2 inhibitors could reduce peritoneal glucose uptake and improve fluid removal in clinical PD.